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Available online 8 October 2011Abstract Copy number variation (CNV) is a common chromosomal alteration that can occur during in vitro cultivation of
human cells and can be accompanied by the accumulation of mutations in coding region sequences. We describe here a system-
atic application of current molecular technologies to provide a detailed understanding of genomic and sequence profiles of
human embryonic stem cell (hESC) lines that were derived under GMP-compliant conditions. We first examined the overall chro-
mosomal integrity using cytogenetic techniques to determine chromosome count, and to detect the presence of cytogenetically
aberrant cells in the culture (mosaicism). Assays of copy number variation, using both microarray and sequence-based analyses,
provide a detailed view genomic variation in these lines and shows that in early passage cultures of these lines, the size range
and distribution of CNVs are entirely consistent with those seen in the genomes of normal individuals. Similarly, genome se-
quencing shows variation within these lines that is completely within the range seen in normal genomes. Important gene classes,
such as tumor suppressors and genetic disease genes, do not display overtly disruptive mutations that could affect the overall
safety of cell-based therapeutics. Complete sequence also allows the analysis of important transplantation antigens, such as
ABO and HLA types. The combined application of cytogenetic and molecular technologies provides a detailed understanding
of genomic and sequence profiles of GMP produced ES lines for potential use as therapeutic agents.
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The development of cell-based therapeutics for clinical ap-
plications will continue to require rigorous quality control
of the chromosomal and genetic integrity. The process of
in vitro propagation of human cells can often lead to a dis-
ruption of DNA integrity whether analyzed at the level of
whole genomes, individual chromosomes or at base pair res-
olution. Trisomies 12 and 17 has been reported in long-term
cultures of hESCs (Draper et al., 2004), while more recently,
higher resolution methods for identifying copy number vari-
ation (CNV), such as comparative genomic hybridization
(CGH) and array-based profiling, have reported a much
broader spectrum of chromosomal amplifications and dele-
tions that vary substantially with both cell strain and propa-
gation history (Laurent et al., 2011; Hussein et al., 2011;
Lefort et al., 2008; Spits et al., 2008). Whole genome re-
sequencing is now being applied to the assessment of cul-
tured cells and has shown that induced pluripotent stem
(iPS) cell methods can lead to the accumulation of point mu-
tations in the resulting clonal population (Gore et al., 2011).
Similarly, iPS cells can display substantial differences in
their epigenetic profiles compared to embryonic stem cells
(Lister et al., 2011).
While the current methodologies for genome and se-
quence analysis provide unprecedented resolution for iden-
tifying potential variance in cell cultures, the impact of
any specific variance may not be easily predicted. Aneuploi-
dy is generally considered to be an unambiguous quality con-
trol issue for human cell-based therapies given that
chromosomal aberrations can result in increased risk of on-
cogenic transformation (McClendon et al., 2008). Similarly,
rare and common DNA variations that modulate disease risk
should be assessed, particularly for genes whose functional
disruption can lead to transformation. Of less obvious impact
on the safety and performance of cellular therapeutics are
smaller scale changes in gene copy number, coding sequence
variance, or disease-associated alleles. Sequence variance in
the genome occurs predominantly at the level of CNV or sin-
gle nucleotide variance (SNV) and for cells intended for
human therapies, normal genomes can provide a useful
comparator.
Here we described a comprehensive analysis of chromo-
somal and gene variance in 5 human ES cell lines that were
derived using GMP compliant methods (Crook et al., 2007).
We first analyzed the overall karyotype using G-banding to
ensure overall chromosomal integrity and then used FISH
probes to detect the presence of emerging clones with al-
tered chromosomal copy number. Short tandem repeat
(STR) fingerprints were derived for each line and can be
used to track long-term cultures and derivatives while telo-
mere length analysis confirmed the embryonic potential of
these lines for long term propagation. Our review of copy
number variation applies two orthogonal methods and then
compares the resulting variants to those seen in normal ge-
nomes. Similarly, we compare sequence variance directly
to normal genomes to achieve a balanced review of non-
conservative variance seen in specific gene classes, such as
tumor suppressors, and in disease-associated alleles, such
as APOE. By each of these measures, early passage cultures
of these lines display variance that is entirely consistent
with that seen in normal individuals. Finally, we reviewspecific transplantation-related antigens that can now be
assessed by sequence-based methods.
Results
hES cell culture
The ESI lines described here were derived with GMP-
compliant derivation procedures and were initially expanded
on human fibroblast feeder cultures (Crook et al., 2007). We
routinely culture hESC lines in ES culture medium (mTeSR1;
StemCell Technologies); an assessment of hESC-related cell
surface markers showed high level expression in ESI lines cul-
tured on Matrigel (Table S1).
Analysis strategy
Our assessment of hESC cultures applied both cell-based and
DNA-based analysis to the preparations. Genomic DNA samples
are collected for multiple applications, including STR finger-
printing, telomere length analysis, CNV assessment and com-
plete genome sequencing (Fig. 1). Cell cultures are used for
cytogenetic assessment. G-band karyotyping provides an over-
all review of chromosome count and integrity, and can be par-
ticularly useful in defining several chromosomal aberrations,
including balanced translocations and inversions, that can be
difficult to detect by SNP-based techniques. All 5 ESI lines
tested showed a normal human karyotype, with 4 female
(XX) and 1 male lineages (Figs. 2A, B). To better assess culture
mosaicism, we applied FISH probes to interphase nuclei
that detect the short arm of chromosome 12 (ETV-6) and the
centromere of chromosome 17, two of the most widely
reported aneuploidies seen in cultured human cells (Meisner
and Johnson, 2008). Although four of five ES cultures had a
normal diploid signal pattern for both probes, culture ESI 051
demonstrated three 12p13 (ETV6) signals in 4% OF 200 inter-
phase nuclei, consistent with an emerging clone with trisomy
12 (Figs. 2A, C). We did not observe copy number variation
at the ETV-6 locus for ESI051, using either SNP-based arrays
or sequencing-derived methods, as would be expected given
the low frequency of these cells in the population. Homoge-
nous assays, such as those applied to DNA prepared from cell
culture, have a limited ability to detect low levels of aberrant
cells within a culture compared to FISH.
STR fingerprinting has become the international standard
procedure for tracking cellular identity (Schweppe et al.,
2008) and is particularly useful in manufacturing, where mo-
lecular authentication of derivative cell lines is required.
Each of the ESI lines provides a unique identifier and as
expected, H9 was returned as an identity hit when the
STR-based fingerprint was queried against the NIH Embryon-
ic Stem Cell Registry (http://grants.nih.gov/stem_cells/
registry/current.htm) (Fig. 2A).
We routinely assess ES and primary cell cultures for telo-
mere length since this parameter directly correlates with
replicative lifespan in cultured somatic cells (Allsopp et
al., 1992). As expected, all hESC lines tested express active
telomerase (data not shown) and have mean telomere
lengths in the 8–20 kbp range, typical of other hESC lines
and sperm (Figs. 2A, D).
In vitro cell culture
FISH
Genomic DNA
G-banding Karyotype
(gross abnormalities, polyploidy,
mosaicism)
(gene copy number,
high resolution mosacism)
STR Fingerprint Telomere Length
Assessment
Copy Number Variation
SNParray analysis (indels, polysomy)Complete GenomeSequence
(mutations, CNV, alleles)
Figure 1 Overview of ES cell analysis strategy. ES lines ESI017, 035, 049, 051 and 053 were expanded using feeder-free culture from
early passage frozen stocks. Cultures were evaluated for G-banded karyotype, STR fingerprinting and FISH-based assessment of chro-
mosomes 12 and 17 (Methods). High molecular weight DNA was harvested for telomere length analysis, copy number variation deter-
mination and complete genome sequencing.
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We evaluated CNVs in the ESI lines using two methods: SNP-
based arrays (HumanCytoSNP-12, and GenomeStudio Geno-
typing Module, Illumina) and whole genome sequence-
based methods (Complete Genomics, Inc.).A
Cell Line Passage Karyotype STR fingerprint*
ESI017 28 46, XX Unique
ESI035 22 46, XX Unique
ESI049 24 46, XY Unique
ESI051 23 46, XX Unique
ESI053 20 46, XX Unique
H9 32 46, XX Match-H9
B C
1 2 3 4 5
6
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19 20 21 22 X Y
14 15 16 17 18
7 8 9 10 11 12
Figure 2 Karyotype, FISH, STR and TRF analyses. A: Summary of
pared NIH Embryonic Stem Cell Registry (http://grants.nih.gov/stem
(www.ATCC.org). H9 scored the appropriate identity hit registered w
ESI017. C: Representative diploid interphase nuclei from cell line ESI0
ern blot analysis of TRF length. ESI lines show telomere lengths ap
(XGene) show significantly shortened TRFs.SNP-called CNV
The average spacing of this array (300K SNP) is approximate-
ly 10 kbp and as such, can be used to identify variants that
span 50 kbp or larger. Call rates for all samples averaged
N99% (data not shown). We reviewed CNVs that had highG-band p12, Mean TRF 
(abnormal/normal)
 17cen FISH
(abnormal/ normal) (kbp.)
0/20 0/200 13.7
0/20 0/200 14.9
0/20 0/225 14.0
0/20 9/225 p12 trisomy 9.8
0/20 0/200 14.5
0/20 0/300 15.0
D
results for 5 ESI lines and H9. STR fingerprint results were com-
_cells/registry/current.htm) and the ATCC Cell Line Repository
ith ATCC. B: Apparently normal G-banded karyotype for cell line
17 using 12p13 (ETV6) and 17 centromere FISH probes. D: South-
propriate for embryonic lines, while normal dermal fibroblasts
AB
Figure 3 Copy number variance (CNV) from SNP arrays. A: Summary of SNP-based analysis of copy number variance. CytoSNP12 ar-
rays (Illumina) were used to assess high confidence CNVs in ESI lines. Some lines were assessed at several different passages. Genomic
intervals are indicated along with affected genes or gene intervals. Overlap of these intervals with those reported for normal human
genomes in the Database of Genomic Variants (DGV) (Zhang et al., 2006) is indicated. Overlap with gene sets for tumor suppressors,
oncogenes, or OMIM cartilage disease genes (Fig. S2) are indicated. B: Representation of Database of Genomic Variants (DGV) cover-
age for a chromosome X CNV identified in ESI017. Cytogenetic position, overlapping genes (pink) and CNVs seen in normal human ge-
nomes are indicated for this interval (blue: gain; red: loss; brown: gain and loss).Copy number variance (CNV) from SNP arrays.
A: Summary of SNP-based analysis of copy number variance. CytoSNP12 arrays (Illumina) were used to assess high confidence CNVs
in ESI lines. Some lines were assessed at several different passages. Genomic intervals are indicated along with affected genes or
gene intervals. Overlap of these intervals with those reported for normal human genomes in the Database of Genomic Variants
(DGV) (Zhang et al., 2006) is indicated. Overlap with gene sets for tumor suppressors, oncogenes, or OMIM cartilage disease genes
(Fig. S2) are indicated. B: Representation of Database of Genomic Variants (DGV) coverage for a chromosome X CNV identified in
ESI017. Cytogenetic position, overlapping genes (pink) and CNVs seen in normal human genomes are indicated for this interval
(blue: gain; red: loss; brown: gain and loss).
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158 W.D. Funk et al.confidence scores (N100) as this cut-off consistently cap-
tured the same CNVs in technical replicates (data not
shown). Using this sift, the majority of CNVs identified in
the ESI lines were larger than 100 kb. Early passage cultures
of the ESI lines typically displayed fewer than 5 high-
confidence CNVs with sizes ranging from 0.2 to 2 Mbp
(Fig. 3A). These CNVs were found to be predominantly within
regions previously annotated in databases of variance found
in normal human genomes (Database of Genomic Variants
(DGV); Zhang et al., 2006). For example, a 1.59 Mbp CNV
seen in early passage cultures of ESI017 covers a region in
which both an increase and decrease in copy number is
reported in DGV (Fig. 3B). The total number of potentially
affected genes in this analysis of the ESI lines ranged from
0 to 20 and similar CNVs and affected gene numbers were
seen in early passages of the ES lines H1 and H9 (Fig. 3A).
The CNVs seen in early passage cultures of the hESC lines
were retained in later passage cultures but new variance
arose with longer-term culture. For example, later passage
ESI049 cultures (P36) showed a loss of heterozygosity (LOH)
of the q arm of Chr 17, while a substantial amplification of
q17 was also seen in later passage (p49) H9 cultures
(Fig. 3A), alterations that have been reported in both cyto-
genetic and array-based assessments of long-term cultures
of human cells (Laurent et al., 2011; Draper et al., 2004).
We reviewed the potential overlap of all CNVs with subsets
of genes, including 169 identified tumor suppressor genes
and 198 oncogenes (http://www.binfo.ncku.edu.tw/TAG/
GeneDoc.php) (Table S2). In these early passage cultures,
we did not observe CNVs that overlapped with any of the
tumor suppressor or oncogene exonic sequences (Fig. 3A).
As a further demonstration of this approach, we analyzed
subsets of genes that would be predicted to be impactful
on the development of a tissue-specific cellular therapeu-
tics. We extracted over 70 genes from OMIM (http://www.
ncbi.nlm.nih.gov/omim/) reported to be mutated in human
genetic diseases affecting cartilage development, mainte-
nance and disease propensity (Table S2). Again, no early pas-
sage cultures had CNVs that affected the gene count for this
set.CNV SizeRange
(kbp) ESI017 ESI035 ESI049 ESI051 ESI053
Normal Genome
Median*
>1, <=5 27 25 30 23 23 23
>5, <=20 113 100 105 118 113 113
8 3>20, <=100 45 41 40 4 38 4
>100, <=1000 7 8 3 6 6 5
>1000 1 0 0 0 0 0
A
Figure 4 CNV analysis from complete genome sequencing. A: CNVs
sent CNV interval length. Comparison to CNVs from sequence analysi
diagram (Krzywinski et al., 2009) representing the distribution of CNV
Bar width is proportional to CNV size interval. Outer rim shows G-banGenome sequence-called CNVs
Effectively, CNVs can be estimated by comparing read-
depth calls to those expected from the reference genome
(Methods). Sequence-called CNVs confirmed several of the
SNP-called CNVs with the exception of those that were elim-
inated due to genome build formats (SNP data was Build 36,
genome data was from Build 37), or from chromosomal loca-
tions not covered by SNPs in the array format (data not
shown). The sequence-based CNV algorithms assess read
depths on a 1 kbp scan window and thus can identify
CNVs at finer resolution than the CytoSNP12 arrays used in
this study. To provide a relevant metric for this analysis,
we compared CNVs in the sequenced ESI cell lines with
those identified in 46 genomes from normal human donors
sequenced on the same platform (Complete Genomics,
Table S3). The overall size distribution of CNVs was similar
between ESI lines and human genome samples, with the ma-
jority of CNVs falling in the 5–20 kbp range (Fig. 4A). The
chromosomal distribution of CNVs in the ESI lines appeared rel-
atively unbiased and did not differ in size or distribution from
that of the normal genome samples (Fig. 4B). Furthermore,
the majority of CNVs detected by this analysis occurred in re-
gions defined either as segmental duplication, or low com-
plexity, such as LINE, SINE and LTR sequences and were
annotated in the database of genomic variance (Table S4).Complete genome sequence
We performed complete genome re-sequencing of the 5
ESI lines using a commercial adaptation of the combinatorial
probe anchor ligation (cPAL) chemistry and DNA nanoballs;
variants were called and scored using a local de novo assem-
bly methodology (Complete Genomics, Inc; Drmanac et al.,
2010). Re-sequencing maps raw reads to a reference genome
(NCBI Build 37) and reports variance compared to the hap-
loid genome reference. We concentrated our initial analysis
on exonic and coding (cds) sequences as these are most typ-
ically disrupted in human genetic disease. Haploid readESI017
NA19700
NA1852
NA19017
B
were extracted and sized from the genome sequence. Bins repre-
s of 46 normal human genomes (*Table S4) is indicated. B: Circos
s identifies in on Chr 1 for ESI017 and 3 normal human genomes.
ding for Chr1.
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to those reported previously while the % of fully called
sequence for exonic and cds sequences was 96–97%
(Table S5). Since our sequence analysis is compared only to
the reference build, we again used genome sequences from
normal donors (Table S3) sequenced using the identical plat-
form for comparison of variant profiles. To identify poten-
tially disruptive variants in the exonic regions of the
genomes, we used ANNOVAR (Wang et al., 2010) an infor-
matics software tool, to identify and sort potential sequence
variants (Fig. 5). In comparison to 46 normal human genomes
analyzed using the same sequencing platform, the early pas-
sage ESI lines displayed a frequency of potentially disruptive
exonic variations, including frame-shift insertion/deletions,
nonsense substitutions, splice donor/acceptor changes and
non-synonymous substitutions that fell within the normal ge-
nome range (Fig. 6). We then asked whether potentially dis-
ruptive variants fell within important gene classes. Similar to
the results seen in the complete genome exome, non-
synonymous substitutions were the predominant variants iden-
tified in the analysis of tumor suppressor genes (Table S2)
(Fig. 6), however the impact of substitutions that do not direct-
ly alter coding sequence can be difficult to assess by3.826M character
3.818M filtere
13,554 total exon
varian
2,864 variants af
synonym
2,558 va
Tumor Suppressor/Oncogenes 
Tissue-relat
Figure 5 Sequence variance analysis strategy. Sequence variants
using a modified version of ANNOVAR (Wang et al., 2010). SIFT (Ng a
Exonic variants are then contrasted against specific gene sets.informatics alone. Frameshift or nonsense mutations could be
impactful in terms of tumor suppressor gene function and we
identified a single frameshift variant affecting tumor suppres-
sor genes in ESI017 (EGR1), ESI053 (AIM2) and ESI049
(COL18A1) (Fig. 6). Two of these genes (EGR1, COL18A1) have
been identified as loss of copy number variants in normal ge-
nomes (DGV; data not shown). This would suggest that even
complete loss of a single copy of these genes may be less likely
to be considered impactful. Similarly, the distribution of vari-
ance in a large collection of defined oncogenes (Table S2)
showed similar substitution frequencies in ESC and normal ge-
nomes (Fig. 6).ABO, ApoE and HLA variants
Complete genome sequence can also serve to provide initial
information on disease propensity alleles and transplantation-
related markers of cellular therapeutics. The ABO blood type is
defined by the 3 alleles of the ABO gene (Fig. 7A). A review of
these in the sequence of the ESI lines showed unambiguous al-
lele calls reflecting OO, AO and AA blood types. These were
confirmed using a multiplex PCR assay (Lee et al., 2011)ized variants 
d variants 
Remove low impact variants 
From SIFT analysis 
ic and splicing 
ts 
Remove synonymous and non-
frameshift exonic variants 
ter removal of 
ous 
Remove variants in regions of 
segmental duplication 
riants 
ed genes 
Human Genetic Disease 
Remove intergenic and intronic 
variants, dominant model 
that differ from the reference build (NCBI Bld37) were assessed
nd Henikoff, 2001) identifies and removes low impact variants.
Figure 6 Summary of exonic sequence variants from analysis strategy (Fig. 5). Sequence variants of the indicated type were scored
for each ESI line in comparison to a range (or average) of the same variant types in 46 normal human genomes (*Table S3), including
total exonic variants, exonic variants found in tumor suppressor genes (Fig. S2), and exonic variants found in protooncogenes (Fig.
S2). For frameshift and stopgain (nonsense) variants in the ESI lines, the affected genes are indicated.
160 W.D. Funk et al.(Figs. 7C, S1). Given the significant impact of ApoE genotypes
on cardiovascular and Alzheimer's disease propensities, we
reviewed the ESI line genomes for the 3 major ApoE alleles
(E2, E3, E4). The processed sequence suggested calls for cell
lines ESI017 and 051 (Fig. 7A), while half calls and no calls pre-
vented the determination of the genotypes at the high confi-
dence threshold for the remaining lines. A review of the
evidence files for these genomes revealed a very low read
depth across these positions (4–6 reads) (data not shown). We
performed multi-plex PCR-based analysis of APOE alleles and
confirmed the determination calls for the two lines and
assigned ApoE genotypes for the remaining lines (Figs. 7B, S2).
None of the ESI lines, nor H1 and H9, carry the potentially del-
eterious ApoE4/E4 genotype.
Similarly, sequence calls across the classical HLA loci
were insufficient for unambiguous typing, as both the com-
plex variance at these loci and issues of phase determination
represent significant technical hurdles for this application.
Amplification and re-sequencing of the genomic loci for the
HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 genes pro-
vided allele calls for each cell line (Fig. 7D). Three of the
most frequently occurring HLA haplotypes in American popu-
lations (Maiers et al., 2007) are compatible with the ob-
served phenotypes of ESI017 (A*01:01–B1*08:01C*07:02DRB1*03:01), ESI035 (A*03:01–B*35:01C*04:01 DRB1*01:01),
and ESI051, 053 (A*03:01–B*07:02C*07:02 DRB1*15:01).Discussion
We report here a set of methodologies intended to provide a
complete and thorough review of the genome integrity of
cellular therapeutics. Our approach includes a review of
the chromosomal integrity and for the first time, a careful
review of the genome sequence integrity of cell lines de-
rived using GMP-compliant processes and documentation.
Importantly, we have compared the occurrence of variance
in terms of type, size and distribution and conclude that at
early passage, hESCs are entirely consistent with variance
seen in normal human genomes. Given the importance of
cellular integrity for cell therapeutic applications, reviewing
the genome and sequence integrity for these same products
will likely become a standard requirement for non-
autologous therapeutics.
Extended in vitro expansion of hESC and other cultured
human cells most often results in large scale chromosomal
abnormalities, as has been documented using cytological
methods (Draper et al., 2004) and more recently, SNP and
AB
D
C
Figure 7 Evaluation of ABO, ApoE and HLA allelic variants. A: Genome sequence was evaluated directly for ABO and ApoE allele
status. ABO alleles could be called unambiguously from the sequence reads. ApoE alleles for ESI 017 and 051 were called, alleles for
ESI035, 049 and 053 were not called due to low read coverage. B: TaqMan assay results for ApoE alleles (E2, E3, E4) (Fig. S2). C: Multiplex
PCR assay results for ABO blood type alleles (Fig. S1). D: HLA typing of 10 major HLA alleles. Genomic DNA was amplified across 10 major
HLA alleles and re-sequenced.
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et al., 2006). We confirm here the propensity of later stage
cultures to show examples of classical karyotypic abnormal-
ities, such as chromosome 12 and 17 aneuploidy. Important-
ly, cytological methodologies can detect these variances
even when present in a small minority of cells in a culture
and provide early evidence of cultures that begun to drift
(Meisner and Johnson, 2008). The application of multiple
FISH probes should allow an even sharper detection of the
emergence of common chromosomal variants in cultured
populations.
Array and complete genomic hybridization-based
methods are now being used to detect deletions and amplifi-
cations that are considerably shorter than the resolution of
cytogenetic techniques. Our data provides additional evi-
dence of accrual of CNVs with extended culture, potentially
as a result of replicative stress and culture adaptation
(Narva et al., 2010; Baker et al., 2007). We applied two or-
thogonal methods (SNP array and sequence-based detection)to identify these variances. Replicate analyses using array-
based methods showed good reproducibility for high confi-
dence CNVs, while sequence-based methods confirmed
some, but not all CNVs detected by arrays, suggesting that
alternate methods can provide complementary information.
Importantly, the vast majority of CNVs identified in these
early passage cultures have been previously described in da-
tabases that curate CNVs in normal human genomes (Iafrate
et al., 2004) and these sequence intervals typically show low
sequence complexity, as demonstrated by the preponder-
ance of LINE elements and regions of segmental duplication
in these intervals. Sequence-based detection of CNVs allowed
for the direct comparison of hESC lines to normal human ge-
nomes and by all measure of size, distribution and affected
genes, CNVs found in these early passage ES cultures were en-
tirely within the range of normal genome variation.
Complete genome sequencing methodologies and annota-
tion provide sequence resolution that allows for the initial de-
tection and cataloging of variance, although the accuracy or
162 W.D. Funk et al.completeness of calling a diploid genome is limited by the re-
quirement for relatively deep sequence coverage. Clearly, or-
thogonal methods that confirm or complete sequence-based
variance determinations remain a necessity. We confined our
initial analyses to variance that could reliably be predicted to
affect the expression of gene products from protein-encoding
genes.
As opposed to iPS cell studies, where de novomutations that
have been cataloged between progenitor and iPS derivatives
(Gore et al., 2011), hESC lines have not yet been directly com-
pared to the genomes of the donor embryos (nor can they be
compared to the parental IVF donors). However we show that
by all measures of nucleotide-level variance, these early pas-
sage ES lines show variance that is entirely within the range
seen in normal human genomes. hESC lines have been shown
to have effective means to ensure genome integrity, such as
enhanced apoptosis of mutated cells and enhanced mitotic re-
combination (Filion et al., 2009; Hong et al., 2007), however
maintenance of this integrity is challenged continually in long
term in vitro cultures. The analysis of genome and sequence in-
tegrity can be applied to select an appropriate progenitor line,
and should then be repeated at regular intervals during the ex-
pansion and derivation of cell populations.
Further focusing these analyses on gene sets that are of spe-
cific concern for developing therapeutic products (tumor sup-
pressor/oncogenes), we see no appreciable difference in the
variance found in hESC vs. normal human genomes. This same
type of analysis can be applied to inherited disease genes
(OMIM), disease propensity alleles (GWAS (Hindorff et al.,
2009)), or mutation databases (HGMD) (Stenson et al., 2009)
and would then allow for the selection of cell lines that lack
deleterious variants or mutations. The evaluation of APOE al-
leles is a prime example of this approach. Although the direct
cellular mechanisms by which the E4/E4 allelic combination
contributes to late onset Alzheimer's disease are likely com-
plex, clearly avoiding this combination when choosing a cell
line for developing neuronal applications would seem prudent.
We demonstrate here that the evaluation of transplantation-
related alleles, such as ABO and HLA can also be evaluated di-
rectly from sequence data and this can allow for the selection
of specific cell lines for specific therapeutic applications (e.g.
Blood type OO for the development of erythrocyte progenitors).
In spite of high reported accuracy of the cPAL sequencing
methods (Drmanac et al., 2010), orthogonal methods that con-
firm or complete sequence-based variance remain a necessity
until an expected clinical genome quality is achieved in this rap-
idly developing field.
Experimental procedures
Cell culture
The ESC lines ESI017, 035, 049, 051 and 053 (Crook et al.,
2007) and H1, H9 were cultured from research-grade cell
banks on matrigel-coated culture plastic (Ludwig et al.,
2006; Rosler et al., 2004). Briefly, hESC lines were cultured
on tissue culture plastic coated with Growth Factor Reduced
Matrigel (Becton-Dickenson, Inc) in mTeSR1™ medium (Stem
Cell Technologies, Inc.) hESC were passaged weekly (1:3 or
1:4 split ratio) using 5 mM EDTA (Invitrogen, Inc.) or Accu-
tase (Innovative Cell Technologies, Inc.), and supplemented
with 10 μM of Rock Inhibitor, Y-27632 (Tocris Bioscience) atplating. FACS-based assessment of markers was performed
using an Accuri C6 Flow Cytometer with CSampler and
CFlow Sampler Software (Accuri) and antibodies listed in
Table S1.
Cytogenetic analyses
Cultures of ESI lines were evaluated at Cell Line Genetics,
Inc. (Madison, WI) for G-banded karyotype analysis and
FISH assessment of interphase nuclei using probes for ETV6
(12p) and the chromosome 17 centromere as described
(Meisner and Johnson, 2008).
DNA preparation
Total genomic DNA was prepared from by using the QIAGEN
Blood & Cell Culture DNA Kit (Qiagen).
STR fingerprinting
Analysis of genomic DNA for 15 STR loci plus Amelogelin was
performed at Cell Line Genetics, Inc. (Madison WI).
TRF analysis
Mean TRF lengths were determined by non-radioactive
Southern blotting using the TeloTAGGG Telomere Length
Assay kit (Roche).
SNP array CNV analysis
Genomic DNA samples were analyzed at the Biomedical Ge-
nomics Center usingCytoSNP12 BeadChip kits (Illumina)
using the BeadStudio2009.2 software (Illumina). Call rates
were greater than 99.1%. Normalized intensity ratios
(logR), B allele frequencies (BAF) and CNVs were extracted
using the GenomeStudio Genotyping Module (Illumina).
CNVs with confidence scores greater than or equal to 100
were included in subsequent analyses.
Genome sequencing
Genomic DNA samples were analyzed at Complete Geno-
mics, Inc. (Mountain View, CA). Paired end library prepara-
tion and sequence-by-ligation methods were applied as
described (Drmanac et al., 2010). Reads were mapped to
the NCBI reference genome (Build 37) and data for each ge-
nome sample were provided as listing of sequence variants
relative to the reference genome.
Genome sequence CNV analysis
The “cnvSegmentsBeta files” from the Complete Genomics
data files were first filtered to remove potential CNVs
that were annotated as having “invariant counts”: (non dip-
loid copy number that is invariable in normal genomes), or
“hypervariable counts” (highly variable in normal human ge-
nomes) or were from mitochondrial sequence. The remain-
ing calls indicating an increase or decrease from the
reference copy number were tabulated.
163Evaluating the Genomic and Sequence Integrity of human ES cell lines; Comparison to Normal GenomesABO genotyping
Genomic DNA samples were analyzed using multiplex allele-
specific primer sets for the ABO gene as described (Lee et
al., 2011).
ApoE genotyping
Genomic DNA samples were analyzed using TaqMan primers
(Roche) for alleles rs7412 and rs429358 according as de-
scribed (Julian et al., 2009) using an ABI7500 BioAnalyzer.
HLA typing
Genomic DNA samples were analyzed by high resolution re-
sequencing of the indicated loci (Histogenetics, Inc.) as de-
scribed (Noreen et al., 2001).
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.10.001.
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